Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 3, 2002, Pages 243-250

  Shen, Meiyu ^a,b   Schilder, Russell J ^a,b   Obasaju, Coleman ^a,b   Gallo, James M ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

High dose carboplatin; Limited sampling model; Population pharmacokinetic model

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CREATININE; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; OVARY CARCINOMA; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; POPULATION MODEL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VALIDATION PROCESS;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; OVARIAN NEOPLASMS;

EID: 0036051251     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0490-y     Document Type: Article

References (25)

1. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
2. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II
3. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
4. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
5. Population pharmacokinetics of carboplatin in children
6. Prediction of creatinine clearance from serum creatinine
7. Clinical pharmacokinetics and dose optimisation of carboplatin
8. Prospective validation of a pharmacologically based dosing scheme for the cis-diaminedichloroplatinum (II) analog diaminecyclobutane dicarboxylatoplatinum
9. Population pharmacokinetic model for topotecan derived from phase I clinical trials
10. Pharmacokinetics of cis-diamine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function
11. Creatinine clearance bedside estimate
12. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
13. Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
14. Building population pharmacokinetic-pharmacodynamic models
15. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diamino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells
16. Clinical pharmacokinetics of carboplatin
17. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen
18. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells
19. A phase I trial of multiple cycles of high dose carboplatin-paclitaxel-topotecan with peripheral blood stem cell support as front-line therapy
20. Renal handling of carboplatin
21. A limited sampling method for estimation of the carboplatin area under the curve
22. Clinical pharmacokinetics of carboplatin
23. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination